KYOTO - A Kyoto-based regenerative medicine company is launching a service that will allow individuals to generate and store induced pluripotent stem cells from their own blood for potential future use.
Starting in April, iPS Portal Inc. will offer a service in collaboration with pharmaceutical experts that features strict quality standards and monitoring. The initial cost of cell production and related processes is estimated to be between 10 million yen ($63,000) and 20 million yen.
Log in or create a Free Membership
Account
Log in
or
Create accountFree Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
Related coverage:
